Abexinostat

Overview

Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma	2023/01/26	NCT05698524	Phase 1	Recruiting	University of Nebraska
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	2020/08/04	NCT04498520	Phase 1	Withdrawn	Pamela Munster
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients	2019/07/18	NCT04024696	Phase 1	Active, not recruiting	Xynomic Pharmaceuticals, Inc.
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma	2019/05/06	NCT03939182	Phase 1	Completed	Memorial Sloan Kettering Cancer Center
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)	2019/05/03	NCT03936153	Phase 2	Recruiting	Xynomic Pharmaceuticals, Inc.
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma	2019/05/02	NCT03934567	Phase 2	Active, not recruiting	Xynomic Pharmaceuticals, Inc.
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma	2018/07/26	NCT03600441	Phase 2	Active, not recruiting	Xynomic Pharmaceuticals, Inc.
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)	2018/07/19	NCT03592472	Phase 3	Recruiting	Xynomic Pharmaceuticals, Inc.
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies	2018/07/18	NCT03590054	Phase 1	Completed	Rahul Aggarwal
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer	2010/06/23	NCT01149668	Phase 1	Completed	Pharmacyclics LLC.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access